文献

J-GLOBAL ID：201802253476387081   整理番号：18A0492412

黒色腫における構造的に無関係なH3K9デメチラーゼの老化優先協調活性を標的にする【Powered by NICT】

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma

著者 (34件)： Yu Yong (Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany) ,  Schleich Kolja (Charite - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, ...) ,  Yue Bin (Charite - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, ...) ,  Ji Sujuan (Charite - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, ...) ,  Lohneis Philipp (Charite - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Institute of Pathology, 10117 Berlin, Germany) ,  Kemper Kristel (Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands) ,  Silvis Mark S. (Department of Surgery, University of Utah Health Sciences Center & Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA) ,  Qutob Nouar (Weizmann Institute of Science, Department of Molecular Cell Biology, Rehovot 7610001, Israel) ,  van Rooijen Ellen (Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA) ,  van Rooijen Ellen (Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 02138, USA) ,  Werner-Klein Melanie (Regensburg Center for Interventional Immunology (RCI) and University Medical Center of Regensburg, 93053 Regensburg, Germany) ,  Werner-Klein Melanie (Experimental Medicine and Therapy Research, University of Regensburg, 93053 Regensburg, Germany) ,  Li Lianjie (Charite - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, ...) ,  Dhawan Dhriti (Charite - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, ...) ,  Meierjohann Svenja (University of Wuerzburg, Physiological Chemistry, Biocenter, 97074 Wuerzburg, Germany) ,  Reimann Maurice (Charite - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, ...) ,  Elkahloun Abdel (National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA) ,  Treitschke Steffi (Fraunhofer-Institute for Toxicology and Experimental Medicine, 93053 Regensburg, Germany) ,  Dorken Bernd (Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany) ,  Dorken Bernd (Charite - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, ...) ,  Dorken Bernd (Deutsches Konsortium fuer Translationale Krebsforschung (German Cancer Consortium), Partner Site Berlin, Germany) ,  Speck Christian (Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, and MRC London Institute of Medical Sciences (LMS), London W12 0NN, UK) ,  Mallette Frederick A. (Department of Medicine, Universite de Montreal, Maisonneuve-Rosemont Hospital Research Centre, Montreal, QC H1T 2M4, Canada) ,  Zon Leonard I. (Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA) ,  Zon Leonard I. (Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 02138, USA) ,  Holmen Sheri L. (Department of Surgery, University of Utah Health Sciences Center & Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA) ,  Peeper Daniel S. (Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands) ,  Samuels Yardena (Weizmann Institute of Science, Department of Molecular Cell Biology, Rehovot 7610001, Israel) ,  Schmitt Clemens A. (Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany) ,  Schmitt Clemens A. (Charite - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, ...) ,  Schmitt Clemens A. (Deutsches Konsortium fuer Translationale Krebsforschung (German Cancer Consortium), Partner Site Berlin, Germany) ,  Lee Soyoung (Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany) ,  Lee Soyoung (Charite - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Medical Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molekulares Krebsforschungszentrum, 13353 Berlin, ...) ,  Lee Soyoung (Deutsches Konsortium fuer Translationale Krebsforschung (German Cancer Consortium), Partner Site Berlin, Germany)
資料名： Cancer Cell  (Cancer Cell)
巻： 33  号： 2  ページ： 322-336.e8  発行年： 2018年 
JST資料番号： W1844A  ISSN： 1535-6108  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： 癌遺伝子誘発老化,例えば,色素細胞性母斑では,抑制トリメチル化ヒストンH3リジン9(H3K9)マークとそれらのプロモーターの修飾に起因する増殖関連遺伝子の転写サイレンシングを介して前悪性細胞の増殖を停止する。は構造的に異なるH3K9活性デメチラーゼのリジン特異的デメチラーゼ-1(LSD1)といくつかの十文字Cドメイン含有部分(JMJD2Cのような)は老化を無効とRas/Braf誘発形質転換を可能にすることを示した。マウスとゼブラフィッシュモデルにおいて,強制LSD1またはJMJD2C発現はBraf V600E駆動黒色腫発生を促進した。標的化阻害は老化を回復し,Braf阻害剤耐性黒色腫でも,血縁および非血縁H3K9デメチラーゼ活性の集団的アップレギュレーションを呈した確立された黒色腫細胞系及び初代ヒトメラノーマ試料の大きなサブセットはin vivoで二次免疫効果と制御された腫瘍成長を誘発した。Copyright 2018 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【Powered by NICT】

シソーラス用語： *メチルトランスフェラーゼ ,  癌遺伝子 ,  *黒色腫 ,  *老化 ,  プロモーター領域 ,  アップレギュレーション ,  色素性母斑 ,  ターゲティング ,  Rasタンパク質
準シソーラス用語： 動物モデル ,  腫瘍成長 ,  黒色腫細胞 ,  阻害剤 ,  ヒストンH3 , 【Automatic Indexing@JST】

著者キーワード (10件)： Ras/Braf ,  細胞老化 ,  H3K9 ,  ヒストン脱メチル化 ,  JMJD2C ,  LSD1 ,  動物モデル ,  melanoma ,  患者由来異種移植片 ,  標的療法

分類 (3件)： 多糖類  (CF10054P) ,  実験用生物  (EA03070Y) ,  神経の基礎医学  (GN01020W)

タイトルに関連する用語 (6件)： 黒色腫 ,  老化 ,  優先 ,  協調 ,  活性 ,  標的